Document is current
Any future updates will be listed below
-
Authors
Bland, Wesley A.
Mitra, Dipanwita https://orcid.org/0000-0002-4413-0195
Owens, Shana https://orcid.org/0000-0002-2668-9868
McEvoy, Kyle
Hogan, Chad H. https://orcid.org/0009-0002-4114-605X
Boccuzzi, Luciarita
Kirillov, Varvara
Meyer, Thomas J. https://orcid.org/0000-0002-7185-5597
Khairallah, Camille
Sheridan, Brian S.
Forrest, J. Craig https://orcid.org/0000-0002-6695-0936
Krug, Laurie T. https://orcid.org/0000-0002-9648-522X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural funding)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural funding)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA167065)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (Intramural funding)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21AI139580)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21AI139580)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (TR003109)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
G. Harold and Leila Y. Mathers Foundation (MF-1901-00210)
G. Harold and Leila Y. Mathers Foundation (MF-1901-00210)
G. Harold and Leila Y. Mathers Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 11 June 2024
First Online: 24 June 2024
Competing interests
: Craig Forrest, Gang Li, Laurie Krug (divested of future earnings), and Steven Skiena are inventors on US Patent 11,149,255 “Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors.” Docket No.052592-578462 that was issued on October 19, 2021, and expires September 6, 2037. This patented process was used to produce the RDV-OR50.stop virus in this paper to generate high-titer, revertant-free stocks for administration to mice. All other authors declare no competing interests.
